| Description |
KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2[1].
|
| Related Catalog |
|
| Target |
Prostaglandin Receptor[1]
|
| In Vitro |
KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1]. KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM )[2].
|
| In Vivo |
KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1]. Animal Model: male Sprague-Dawley rats (5-week-old)[1]. Dosage: 1, 3, 10, and 30 mg/kg. Administration: Orally once daily beginning 1 day prior to neurectomy for 28 days. Result: Decreased urinary calcium excreation in the neurectomized rats only at 30 mg/kg.
|
| References |
[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3. [2]. Shiwei Wang, et al. A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. bioRxiv. 2020.
|
